Clinical Trials Logo

Spinal Vascular Disorder Nos clinical trials

View clinical trials related to Spinal Vascular Disorder Nos.

Filter by:
  • None
  • Page 1

NCT ID: NCT03280316 Not yet recruiting - Overactive Bladder Clinical Trials

Efficacy Comparison Between Different Management Strategies for Consistent OAB in Patients With SVMs After Surgery

Start date: January 2023
Phase: N/A
Study type: Interventional

The investigators' goal is to compare the efficacy of three different management strategies (sacral neuromodulation, botulinum toxin, M receptor antagonist) in treating consistent OAB in patients with SVMs after surgery.

NCT ID: NCT03280186 Not yet recruiting - Clinical trials for Neurogenic Bladder Dysfunction Nos

Measurement of Bladder Function Change In Patients With SVMs Before and After Surgical Intervention

Start date: January 2022
Phase: N/A
Study type: Interventional

The investigators goal is to create a better understanding of patient with SVMs reported outcomes for bladder management strategies before and after surgery.

NCT ID: NCT03192800 Recruiting - Clinical trials for Spinal Vascular Disorder Nos

Clinical Outcome in Patients With Spinal Dural Arteriovenous Fistulas (COPSDAVF)

COPSDAVF
Start date: March 1, 2013
Phase:
Study type: Observational

Spinal dural arteriovenous fistulas (SDAVFs) are the most common vascular disorder of the spine and account for approximately 70% of spinal vascular malformation.They are a rare pathology with an excepted incidence of only 5-10 new cases per million inhabitants per year. Most fistulas are found in the thoracolumbar region and > 80% of all SDAVFs are located between T6 and L2, whereas the cranio-cervical, cervical and sacral fistulas are more rare. SDAVFs have an overwhelmingly male predominance (80%), with an age presentation in the fifth or sixth dacede. It is presumed that SDAVFs are acquired diseases. A typical SDAVF is located inside the dural mater close to nerve root. It is fed by a radiculomeningeal artery and enters a radicular vein that merges in the perimedullary plexus. The presence of a shunt leads to a reversal of blood flow to the spinal cord venous system, which then induces venous hypertensive myelopathy.